United States

Arena cuts 80 employees

Monday, November 2, 2015

Arena Pharmaceuticals, based in San Diego, has announced plans to improve efficiencies and reduce costs as it focuses on the advancement of its R&D priorities. As part of the initiative, Arena will reduce its U.S. workforce by about 80 employees or 35%, which Arena estimates will reduce annualized cash expenditures for personnel by about $11.0 million. Arena plans to implement additional cost control measures to further reduce its expenditures, including reductions at its Swiss manufacturing facility.

[Read More]

Amgen’s first-in-class oncolytic drug OK’d by FDA

Wednesday, October 28, 2015

The FDA has approved Amgen’s Biologics License Application for IMLYGIC (talimogene laherparepvec), a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable cutaneous, subcutaneous and nodal lesions in patients with melanoma recurrent after initial surgery. [Read More]

Mast Therapeutics initiates phase II vepoloxamer study

Monday, October 26, 2015

San Diego-based Mast Therapeutics, a clinical-stage biopharmaceutical company leveraging its molecular adhesion and sealant technology (MAST) platform to develop novel therapies for sickle cell disease, heart failure, and stroke, has initiated its phase II study of vepoloxamer for the treatment of patients with chronic heart failure. [Read More]

Zafgen updates on beloranib program

Monday, October 26, 2015

Zafgen, a Boston-based biopharmaceutical company dedicated to improving the health and well-being of patients affected by obesity and complex metabolic disorders, has announced a clinical update for beloranib, the company’s lead MetAP2 inhibitor product candidate.

[Read More]

Vaccine Center of Innovation launches

Thursday, October 22, 2015

In an effort to accelerate timelines and decrease development costs of life-saving vaccines, the Infectious Disease Research Institute (IDRI) and Sanofi Pasteur have established the Global Health Vaccine Center of Innovation (GHVCI), to be based at IDRI in Seattle. The project is funded in part by a grant from the Bill & Melinda Gates Foundation. The GHVCI represents an alliance among the three organizations, focused on accelerating the development of vaccines and associated technologies to fight a wide range of global infectious diseases, and ensuring that those critical vaccines are accessible globally, especially to people in need within developing countries.

[Read More]